ATRN

Across TCGA pan-cancer cohorts, ATRN mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ATRN’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ATRN mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ATRN is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, LUAD, and LSCC are the cancer types where ATRN tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATRN mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	−1.011	<.001	12	view →
LUAD	Female	All	−0.693	<.001	9	view →
LSCC	Male	II,III,IV	−0.771	<.001	8	view →
COAD	Female	II,III,IV	−0.517	<.001	7	view →
PDAC	Female	All	+0.372	.001	3	view →
CCRCC	All	All	+0.242	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ATRN–HNSC

Open the HNSC breakdown →